Our scientists discovered a new method for monitoring RNAi activity in blood samples.  The results were presented at the Keystone Gene Silencing by small RNAs symposium (Vancouver, February 7-12).  This new method, circulating extracellular RNA detection (cERD), allows quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid (CSF). [spotlight-link icon="presentation" href="" type="(1.18 MB PDF)"]View our  poster[/spotlight-link] [spotlight-link icon="release" href="" type=""]Read our press release[/spotlight-link]

In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA.  We shared data from two programs within our “Alnylam 5x15” product pipeline, including pre-clinical data from  ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,... [spotlight-link icon="presentation" href="" type="(680 KB PPT)"]View the refractory anemia presentation[/spotlight-link] [spotlight-link icon="presentation" href="" type="(1.88 MB PDF)"]View the hemophilia poster[/spotlight-link] [spotlight-link icon="presentation" href="" type="(112 KB PDF)"]View the beta-thalassemia poster [/spotlight-link] [spotlight-link icon="presentation" href="" type="(435 KB PDF)"]View the erythropoiesis poster[/spotlight-link] [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link]

In September 2011, we and our collaborators presented new data at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society demonstrating substantial new advances in our efforts around systemic delivery of RNAi therapeutics. [spotlight-link icon="presentation" href="" type="(2.1 MB PPT)"]View the LNP Poster[/spotlight-link] [spotlight-link icon="presentation" href="" type="(3.1 MB PPT)"]View the Conjugate Poster[/spotlight-link] [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link]

We have launched our fourth program as part of our Alnylam 5x15 product development strategy.  ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5x15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform. [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="podcast" href="" type="(13.3MB mp3)"]Listen to our CMO discuss the hemophilia program[/spotlight-link] [spotlight-link icon="presentation" href= type="(1.5MB PPT)"]View the slides [/spotlight-link]

Our flagship effort from the Alnylam 5x15 strategy is our ALN-TTR program, which is currently enrolling patients in a Phase I study for the treatment of a disease called transthyretin-mediated amyloidosis (ATTR). [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="" type="(720KB PPT)"]ALNY-PNS-Poster-ALN-TTR-NT-Study-June2011[/spotlight-link] [spotlight-link icon="presentation" href="" type="(1.1MB PPT)"]ALNY-PNS-Poster-ALN-TTR-June2011[/spotlight-link] [spotlight-link icon="presentation" href="" type="(1.0 MB PPT)"] ALN-TTR RNAi Roundtable, July 2010[/spotlight-link]

At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement. [spotlight-link icon="release" href="" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="" type="(1.2MB PPT)"]ALN-VSP PhI ClinicalStudyResults-ASCO2011[/spotlight-link] [spotlight-link icon="presentation" href="" type="(2.2 MB PPT)"] ALN-VSP RNAi Roundtable, May 2011[/spotlight-link] [spotlight-link icon="podcast" href="" type="(3.1MB MP3)"]Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011[/spotlight-link]

In June 2011, our scientists presented an update on our Huntington’s disease program, ALN-HTT, at the 26th Annual HDSA National Convention. [spotlight-link icon="presentation" href="" type="(1.8MB PPT)"]HDSA 2011 Presentation[/spotlight-link]  

In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man using systemically delivered RNAi therapeutics. [spotlight-link icon="release" href="" type=""]Read our press release[/spotlight-link] [spotlight-link icon="podcast" href="" type=""]Dana Farber ALN-VSP Proof of Mechanism[/spotlight-link]

Alnylam scientists and collaborators presented new pre-clinical data from our ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. These data demonstrated, for the first time, that treatment with an RNAi therapeutic can result in regression of...


Receive news and updates on the work at Alnylam that affects you most.